News & Updates

Recent research has found that mutations in the human EZH2 and CCND1 genes may be potential novel biomarkers for liver cancer. The tumour mutation burden (TMB) also appears to be an important prognostic factor and affects patient survival.

While patients with haematological malignancies (HM) are able to mount a persistent antibody response against the spike (S) protein of the SARS-CoV-2 virus, early treatment with rituximab completely abolishes such response, a recent study has found. These findings could help inform coronavirus disease 2019 (COVID-19) vaccination policies for patients with HMs.

Individuals with obesity are at higher risk of developing early-onset colorectal adenocarcinoma compared with their normal-weight counterparts, as reported in a study.

A subanalysis of the ongoing phase II PROFILE 1001 study suggests that MET amplification may serve as one of the predictive biomarkers for response to crizotinib among patients with non-small-cell lung cancer (NSCLC).

A real-world retrospective study reports significantly longer radiological progression-free survival (rPFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide vs abiraterone acetate after previous docetaxel therapy.

Women who follow a healthful plant-based diet have a lower risk of developing breast cancer, especially aggressive tumours, a recent study suggests.

Neither gastric cancer nor gastric dysplasia is seen in patients with corpus atrophic gastritis (CAG) characterized at baseline with corpus pseudopyloric metaplasia (PPM) without corpus intestinal metaplasia (IM) because such lesions are consistently associated with corpus IM, reports a study.

Survival benefit in patients with de novo stage IV nonsmall-cell lung cancer (NSCLC) depends on the type of treatment received, with significantly better median overall survival (OS) seen with the use of small-molecule targeted therapy against epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements than with best supportive care, reports a study.